PHOENIX, AZ--(Marketwired - July 29, 2014) - Insys Therapeutics, Inc. (NASDAQ: INSY) today announced that the Company will release its financial results for the second quarter 2014 on Tuesday, August 12, 2014, before the U.S. financial markets open.
Following the release of the financial results, Michael L. Babich, President and Chief Executive Officer, and Darryl S. Baker, Chief Financial Officer, will host a conference call at 11:00 a.m. Eastern Daylight Time.
Interested parties may participate in the conference call by dialing 888-500-6950 (U.S.) or 719-457-2085 (International), 5-10 minutes prior to the start of the call. A replay will be available shortly after the completion of the call for two weeks by dialing 888-203-1112 (U.S.) or 719-457-0820 (International) and entering conference call ID number 2350568.
A live audio webcast and archive of the call will also be available at www.insysrx.com.
About Insys Therapeutics, Inc.
Insys Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve the quality of life of patients. Using its proprietary sublingual spray technology and its capability to develop pharmaceutical cannabinoids, the company addresses the clinical shortcomings of existing commercial products. The company currently markets two products, Subsys, which is sublingual Fentanyl spray for breakthrough cancer pain, and a generic version of Dronabinol (THC) capsules. The company plans to file a New Drug Application (NDA) for an oral liquid formulation of Dronabinol in the third quarter of 2014 and believes the oral solution formulation has distinct advantages over the current formulation of dronabinol in a soft gel capsule. The company is developing a pipeline of sublingual sprays, as well as pharmaceutical CBD. For more information please visit www.insysrx.com.